LCM
LBPH

Lynx1 Capital Management’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Lynx1 Capital Management’s Portfolio LBPH Stock Details LBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-167,317
Closed -$4.52M – 21
2024
Q2 		$4.52M Buy
+167,317
New +$3.3M 1.63% 8

Other funds holding LBPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return

Lynx1 Capital Management's LBPH Position: Q3 2024 in Review

Lynx1 Capital Management sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q3 2024, closing a stake of 167,317 shares — an estimated $4.52M sold.

Lynx1 Capital Management first reported a position in LBPH in Q2 2024 and held it in 1 quarter. The position peaked at $4.52M in Q2 2024. 125 funds tracked by Wall St. Rank hold LBPH as of Q3 2024.

  • Lynx1 Capital Management reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Lynx1 Capital Management sold 167,317 Longboard Pharmaceuticals, Inc. Common Stock shares in Q3 2024, an estimated $4.52M.
  • Lynx1 Capital Management first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2024 and held it in 1 quarter.
  • Lynx1 Capital Management's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $4.52M in Q2 2024.
  • 125 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q3 2024.

Based on Lynx1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.